Laurion Capital Management’s AstraZeneca AZN Stock Holding History

Laurion Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Sell	6,000 -3,500	-37%	-$658K	0.03%	239
2026 Q1	$1.87M	Hold	9,500	–	–	0.08%	219
2025 Q4	$1.75M	Hold	9,500	–	–	0.07%	108
2025 Q3	$1.46M	Buy	+9,500	New	+$1.44M	0.03%	174
2024 Q3	–	Sell	-38,940	Closed	-$6.07M	–	311
2024 Q2	$6.07M	Buy	+38,940	New	+$5.86M	0.07%	150
2022 Q4	–	Sell	-168,493	Closed	-$18.5M	–	418
2022 Q3	$18.5M	Buy	168,493 +150,880	+857%	+$19.1M	0.11%	144
2022 Q2	$2.33M	Buy	+17,613	New	+$2.31M	0.04%	220
2021 Q4	–	Sell	-6,000	Closed	-$721K	–	557
2021 Q3	$721K	Buy	+6,000	New	+$698K	﹤0.01%	540
2019 Q3	–	Sell	-3,650	Closed	-$301K	–	1011
2019 Q2	$301K	Buy	+3,650	New	+$286K	﹤0.01%	778
2018 Q4	–	Sell	-2,850	Closed	-$226K	–	1103
2018 Q3	$226K	Buy	+2,850	New	+$216K	﹤0.01%	1009
2017 Q3	–	Sell	-351,200	Closed	-$23.9M	–	1547
2017 Q2	$23.9M	Buy	+351,200	New	+$22.9M	0.13%	147

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Laurion Capital Management's AZN Position: Q2 2026 in Review

Laurion Capital Management reduced its AstraZeneca (AZN) stake by 37% in Q2 2026, selling an estimated $658K and leaving 6,000 shares worth $1.14M. The position accounts for 0.03% of the portfolio, ranked #239.

Laurion Capital Management first reported a position in AZN in Q2 2017 and has held it in 11 quarters since. The position peaked at $23.9M in Q2 2017. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Laurion Capital Management held 6,000 shares of AstraZeneca worth $1.14M as of Q2 2026.
Laurion Capital Management sold 3,500 AstraZeneca shares in Q2 2026, an estimated $658K.
AstraZeneca made up 0.03% of Laurion Capital Management's portfolio in Q2 2026, its #239 holding.
Laurion Capital Management first reported a position in AstraZeneca in Q2 2017 and has held it in 11 quarters since.
Laurion Capital Management's AstraZeneca position peaked at $23.9M in Q2 2017.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.